Schilder Christina M, Eggens Petronella C, Seynaeve Caroline, Linn Sabine C, Boogerd Willem, Gundy Chad M, Beex Louk V, Van Dam Frits S, Schagen Sanne B
Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Acta Oncol. 2009;48(1):76-85. doi: 10.1080/02841860802314738.
Previous studies have indicated that a subset of cancer patients treated with chemotherapy show cognitive deficits and/or experience cognitive complaints, whereas literature about the influence of hormonal therapies on cognition is sparse. Because of the accumulating knowledge about the importance of estrogen for cognitive functioning, there is growing concern about adjuvant hormonal therapy for breast cancer (BC) affecting cognition. We examined the cognitive functioning of postmenopausal BC patients who were, following doxorubicin/cyclophosphamide (AC) chemotherapy, randomized to tamoxifen or exemestane, and compared their performance with that of non-cancer controls.
Thirty BC patients using tamoxifen and 50 patients using exemestane underwent interviews, questionnaires and cognitive tests, on average two years after completion of AC chemotherapy. Forty eight healthy controls were tested with similar measures.
Memory complaints were reported by 28% of AC/tamoxifen users, 24% of AC/exemestane users and 6% of healthy controls (p=0.02). Cognitive testing revealed no statistically significant differences between tamoxifen and exemestane users, but suggested that tamoxifen use is possibly related to worse verbal functioning, while exemestane use is possibly related to slower manual motor speed. Both patient groups performed significantly worse than healthy controls on verbal fluency and information processing speed.
Our findings show that sequential treatment of AC-chemotherapy and hormonal therapy in postmenopausal, primary BC is associated with lower test scores for certain cognitive functions, and provide indications for possibly distinctive associations for different types of hormonal treatment. Future research with larger groups is recommended to obtain a more definite picture.
先前的研究表明,接受化疗的部分癌症患者存在认知缺陷和/或有认知方面的主诉,而关于激素疗法对认知影响的文献却很稀少。鉴于雌激素对认知功能重要性的认识不断积累,人们越来越担心乳腺癌(BC)辅助激素疗法会影响认知。我们研究了绝经后BC患者在接受多柔比星/环磷酰胺(AC)化疗后随机接受他莫昔芬或依西美坦治疗后的认知功能,并将他们的表现与非癌症对照组进行比较。
30名使用他莫昔芬的BC患者和50名使用依西美坦的患者在完成AC化疗平均两年后接受了访谈、问卷调查和认知测试。48名健康对照者接受了类似的测试。
28%的AC/他莫昔芬使用者、24%的AC/依西美坦使用者和6%的健康对照者报告有记忆方面的主诉(p = 0.02)。认知测试显示,他莫昔芬使用者和依西美坦使用者之间没有统计学上的显著差异,但表明使用他莫昔芬可能与较差的语言功能有关,而使用依西美坦可能与较慢的手动运动速度有关。两组患者在语言流畅性和信息处理速度方面的表现均明显低于健康对照者。
我们的研究结果表明,绝经后原发性BC患者接受AC化疗和激素疗法的序贯治疗与某些认知功能的测试得分较低有关,并为不同类型的激素治疗可能存在的独特关联提供了线索。建议未来进行更大规模人群的研究以获得更明确的结果。